Targeted Oncology23 小时
Ovarian Function Suppression Improves Survival in Premenopausal Women with HR+, HER2 ...
Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress. An exploratory analysis of the HERceptin Adjuvant (HERA; NCT00045032) trial investigated the benefits of ...
The Punch Newspapers1 天
22-year-old LASU student battles cancer, family seeks N15m financial help
A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...
Targeted Oncology4 天
FDA Approves New Dosage of Trastuzumab Biosimilar for HER2-Overexpressing Cancers
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...
GlobalData on MSN4 天
FDA approves Accord BioPharma’s HERCESSI for cancer treatment
Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...
Monthly Prescribing Reference5 天
Additional Dosage Strength of Biosimilar Hercessi Gets FDA Approval
The Food and Drug Administration (FDA) has approved a 420mg dosage strength of Hercessi ™ (trastuzumab-strf), a biosimilar to Herceptin ® (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...